These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19449763)

  • 21. [Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus].
    Fehér J; Lengyel G
    Orv Hetil; 2007 Dec; 148(49):2331-5. PubMed ID: 18048112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
    Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.
    Soccio RE; Chen ER; Lazar MA
    Cell Metab; 2014 Oct; 20(4):573-91. PubMed ID: 25242225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Insulin sensitizer. A new therapy option for type 2 diabetic patients].
    Filz HP
    MMW Fortschr Med; 2000 Sep; 142(38):31-3. PubMed ID: 11050888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pioglitazone and bladder cancer.
    Ryder RE
    Lancet; 2011 Oct; 378(9802):1544; author reply 1544-5. PubMed ID: 22035551
    [No Abstract]   [Full Text] [Related]  

  • 27. Pioglitazone and bladder cancer.
    Hillaire-Buys D; Faillie JL; Montastruc JL
    Lancet; 2011 Oct; 378(9802):1543-4; author reply 1544-5. PubMed ID: 22035550
    [No Abstract]   [Full Text] [Related]  

  • 28. Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?
    Zheng F; Guan Y
    Kidney Int; 2007 Dec; 72(11):1301-3. PubMed ID: 18004308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats.
    Morsy MA; Ashour OM; Fouad AA; Abdel-Gaber SA
    Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):173-7. PubMed ID: 19566821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of proliferative diabetic retinopathy with insulin use and microalbuminuria.
    Chu SH; Li AH
    Arch Ophthalmol; 2010 Jan; 128(1):146; author reply 146-7. PubMed ID: 20065240
    [No Abstract]   [Full Text] [Related]  

  • 35. Thiazolidinediones and PPARγ agonists: time for a reassessment.
    Cariou B; Charbonnel B; Staels B
    Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.
    Abdin AA; Baalash AA; Hamooda HE
    J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glitazones and the cardiovascular system.
    Devchand PR
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):188-92. PubMed ID: 18316956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
    Strowig SM; Raskin P
    Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.
    Gelman L; Feige JN; Desvergne B
    Biochim Biophys Acta; 2007 Aug; 1771(8):1094-107. PubMed ID: 17459763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.